D Zylla1, M A Kuskowski2, K Gupta3, P Gupta4. 1. Division of Hematology/Oncology/Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN, USA Hematology/Oncology Section, Department of Medicine and Present address: Park Nicollet Health Services, Oncology Research, St Louis Park, MN, USA. 2. Geriatric Research and Education Clinical Center, Minneapolis VA Health Care System, Minneapolis, MN, USA. 3. Division of Hematology/Oncology/Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN, USA. 4. Division of Hematology/Oncology/Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN, USA Hematology/Oncology Section, Department of Medicine and pankaj.gupta@va.gov.
Abstract
BACKGROUND: Pain is associated with shorter survival in non-small cell lung cancer (NSCLC). Lung cancer cells express opioid receptors. Opioids promote angiogenesis, tumour growth, and metastases, and shorten survival in animal models. METHODS: We examined retrospectively if long-term opioid requirement, independently of chronic pain, is associated with reduced survival in 209 patients with stage IIIB/IV NSCLC. Opioid doses were converted to average oral morphine equivalents (OME). Patients were stratified by proportion of time they reported severe pain, and required <5 or ≥5 mg day-1 OME. Effects of pain, opioid requirement, and known prognostic variables on overall survival were analysed. RESULTS: Severe pain before chemotherapy initiation was associated with shorter survival (hazards ratio 1.39, 95% confidence interval, 1.02-1.87, P=0.035). The magnitude of pain and opioid requirement during first 90 days of chemotherapy were predictive of shorter survival: patients with no/mild pain and requiring <5 mg day-1 OME had 12 months longer median survival compared with those requiring more opioids, experiencing more pain, or both (18 compared with 4.2-7.7 months, P≤0.002). Survival differences (16 compared with 5.5-7.8 months, P<0.001) were similar when chronic pain and opioid requirement were assessed until death or last follow-up. In multivariable models, opioid requirement and chronic pain remained independent predictors of survival, after adjustment for age, stage, and performance status. CONCLUSIONS: The severity of chronic cancer-related pain or greater opioid requirement is associated with shorter survival in advanced NSCLC, independently of known prognostic factors. While pain adversely influences prognosis, controlling it with opioids does not improve survival. Prospective studies should determine if pain control using equi-analgesic opioid-sparing approaches can improve outcomes. Published by Oxford University Press on behalf of the British Journal of Anaesthesia 2014. This work is written by (a) US Government employee(s) and is in the public domain in the US.
BACKGROUND:Pain is associated with shorter survival in non-small cell lung cancer (NSCLC). Lung cancer cells express opioid receptors. Opioids promote angiogenesis, tumour growth, and metastases, and shorten survival in animal models. METHODS: We examined retrospectively if long-term opioid requirement, independently of chronic pain, is associated with reduced survival in 209 patients with stage IIIB/IV NSCLC. Opioid doses were converted to average oral morphine equivalents (OME). Patients were stratified by proportion of time they reported severe pain, and required <5 or ≥5 mg day-1 OME. Effects of pain, opioid requirement, and known prognostic variables on overall survival were analysed. RESULTS: Severe pain before chemotherapy initiation was associated with shorter survival (hazards ratio 1.39, 95% confidence interval, 1.02-1.87, P=0.035). The magnitude of pain and opioid requirement during first 90 days of chemotherapy were predictive of shorter survival: patients with no/mild pain and requiring <5 mg day-1 OME had 12 months longer median survival compared with those requiring more opioids, experiencing more pain, or both (18 compared with 4.2-7.7 months, P≤0.002). Survival differences (16 compared with 5.5-7.8 months, P<0.001) were similar when chronic pain and opioid requirement were assessed until death or last follow-up. In multivariable models, opioid requirement and chronic pain remained independent predictors of survival, after adjustment for age, stage, and performance status. CONCLUSIONS: The severity of chronic cancer-related pain or greater opioid requirement is associated with shorter survival in advanced NSCLC, independently of known prognostic factors. While pain adversely influences prognosis, controlling it with opioids does not improve survival. Prospective studies should determine if pain control using equi-analgesic opioid-sparing approaches can improve outcomes. Published by Oxford University Press on behalf of the British Journal of Anaesthesia 2014. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Authors: Antje Gottschalk; Justin G Ford; Cedric C Regelin; Jing You; Edward J Mascha; Daniel I Sessler; Marcel E Durieux; Edward C Nemergut Journal: Anesthesiology Date: 2010-07 Impact factor: 7.892
Authors: Susan Halabi; Chen-Yen Lin; W Kevin Kelly; Karim S Fizazi; Judd W Moul; Ellen B Kaplan; Michael J Morris; Eric J Small Journal: J Clin Oncol Date: 2014-01-21 Impact factor: 44.544
Authors: M H J van den Beuken-van Everdingen; J M de Rijke; A G Kessels; H C Schouten; M van Kleef; J Patijn Journal: Ann Oncol Date: 2007-03-12 Impact factor: 32.976
Authors: Aristomenis K Exadaktylos; Donal J Buggy; Denis C Moriarty; Edward Mascha; Daniel I Sessler Journal: Anesthesiology Date: 2006-10 Impact factor: 7.892
Authors: Miguel A Iñiguez; Antonio Rodríguez; Olga V Volpert; Manuel Fresno; Juan Miguel Redondo Journal: Trends Mol Med Date: 2003-02 Impact factor: 11.951
Authors: Rose Christopherson; Kenneth E James; Mara Tableman; Prudence Marshall; Frank E Johnson Journal: Anesth Analg Date: 2008-07 Impact factor: 5.108
Authors: Susana Garcia-Recio; Gemma Fuster; Patricia Fernandez-Nogueira; Eva M Pastor-Arroyo; So Yeon Park; Cristina Mayordomo; Elisabet Ametller; Mario Mancino; Xavier Gonzalez-Farre; Hege G Russnes; Pablo Engel; Domiziana Costamagna; Pedro L Fernandez; Pedro Gascón; Vanessa Almendro Journal: Cancer Res Date: 2013-09-12 Impact factor: 12.701
Authors: A Carmona-Bayonas; P Jiménez-Fonseca; E Castañón; A Ramchandani-Vaswani; R Sánchez-Bayona; A Custodio; D Calvo-Temprano; J A Virizuela Journal: Clin Transl Oncol Date: 2016-07-21 Impact factor: 3.405